FDA Begins Withdrawal For Midodrine Three Years After It First Threatened To End Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
With no confirmatory studies in sight, agency takes action 14 years after accelerated approval of Shire's hypotension drug ProAmatine, which has since gone generic.
You may also be interested in...
Amid Avastin Noise, Shire Quietly Awaits Word On ProAmatine Public Hearing
The jury is still out on whether Shire’s hypotension drug ProAmatine (midodrine) will be the focus of the same type of public hearing recently held on the fate of Avastin’s metastatic breast cancer claim.
Amid Avastin Noise, Shire Quietly Awaits Word On ProAmatine Public Hearing
The jury is still out on whether Shire’s hypotension drug ProAmatine (midodrine) will be the focus of the same type of public hearing recently held on the fate of Avastin’s metastatic breast cancer claim.
Mylotarg Pulled Off Market, But Pfizer Continues Search For Appropriate Population
After a futile confirmatory trial, Pfizer will review ongoing studies to see if they can be refined to indentify patients that could benefit from the drug, oncology VP Eagle says.